<DOC>
	<DOCNO>NCT00197106</DOCNO>
	<brief_summary>This study conduct investigate whether childhood salmeterol/ fluticasone propionate 50/100 bd deliver via Diskus® inhaler fluticasone propionate 200 mcg bd deliver via Diskus® inhaler non- inferior term symptom control . Additionally aim show salmeterol/ fluticasone propionate 50/100 bd least good term lung function improvement bronchial hyperreactivity enable steroid-sparing management asthma child .</brief_summary>
	<brief_title>Treatment Of Symptomatic Asthma In Children</brief_title>
	<detailed_description>A multicentre , randomise , double blind , parallel group study compare efficacy safety Salmeterol/Fluticasone propionate combination product ( Seretide® ) 50/100mcg Fluticasone propionate ( Flixotide® ) 200mcg , deliver twice daily via DISKUS inhaler , treatment child age 6-12 year symptomatic asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Male female subject age 612 year ( inclusive ) A female eligible enter participate study : nonchildbearing potential ; OR childbearing potential , lactate pregnant . She declare probable become pregnant study ( pregnancy test perform investigator discretion ) Subjects documented history asthma least 6 month Subjects document history BHR within 12 month prior inclusion BHR visit 1 ( PD20 methacholine &lt; 150 mcg equivalence histamine ) Subjects receive BDP , budesonide 100200 mcg bd fluticasone propionate dose 125 mcg bd least 4 week start runin period . Subjects able use electronic peakflow /FEV1 meter ( PIKO1 ) Subjects normal length SD score 2SD +2SD Subjects able use Diskus inhaler Subjects able perform reproducible lung function test visit 1 ( variation FEV1 &lt; 5 % two best measurement ) Subjects guardian , give write informed consent participate study Subjects parent/ guardian able understand complete DRC . The DRC may complete parent/guardian subject unable him/ Subjects able use Ventolin 'as require symptom ' basis Exclusion criterion : Subjects hospitalise asthma within 4 week visit 1 Subjects acute upper respiratory tract infection within 2 week low respiratory tract infection within 4 week prior visit 1 Subjects receive oral , parental depot corticosteroid within 4 week prior visit 1 Subjects know respiratory disorder asthma and/or systemic/thoracic abnormality influence normal lung function Subjects disorder affect growth ( e.g . Turner 's syndrome ) Subjects receive investigational drug within 4 week visit 1 Subjects know suspected hypersensitivity inhale steroid , β2agonists lactose Subjects use medication significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 , include ritonavir ketoconazole Subjects concurrently participate another clinical study Subjects previously randomise trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>salmeterol/fluticasone combination</keyword>
	<keyword>Asthma</keyword>
	<keyword>bronchial hyperresponsiveness</keyword>
	<keyword>Children</keyword>
	<keyword>symptom control</keyword>
</DOC>